The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Victor M. Rivera|Clinical Cancer Research|2016Cited by 325
The utility of MRI in suspected MS [RETIRED]Elliot M. Frohman, W. H. Stuart, Douglas S. Goodin et al.|Neurology|2003Cited by 190
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, Susan Branford, Bronte A. Jamison et al.|Blood|2016Cited by 65
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer modelsRachel M. Squillace, Victor M. Rivera|International Journal of Oncology|2012Cited by 31
Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Victor M. Rivera|Unknown|2023Cited by 0